Shares of SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) climbed 2.7%, building on a previous gain of 2%, following the FDA approval of their drug, GOMEKLI, for the treatment of neurofibromatosis type ...
The dominance of the Magnificent Seven stocks may be fading as investors broaden their focus beyond Big Tech. While the group ...
The Magnificent Seven stocks have cooled off. These consumer staples, energy, financials and healthcare stocks are leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback